De novo tacrolimus extended‐release tablets (LCPT) versus twice‐daily tacrolimus in adult heart transplantation: Results of a single‐center non‐inferiority matched control trial

Extended‐release tacrolimus for prophylaxis of allograft rejection in orthotopic heart transplant (OHT) recipients is currently not FDA‐approved. One such extended‐release formulation of tacrolimus known as LCPT allows once‐daily dosing and improves bioavailability compared to immediate‐release tacr...

Descripción completa

Detalles Bibliográficos
Autores principales: van Zyl, Johanna S., Sam, Teena, Clark, Donna M., Felius, Joost, Doss, Amanda K., Kerlee, Kacie R., Cheung, Zi‐On, Martits‐Chalangari, Katalin, Jamil, Aayla K., Carey, Sandra A., Gottlieb, Robert L., Guerrero‐Miranda, Cesar Y., Kale, Parag, Hall, Shelley A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285033/
https://www.ncbi.nlm.nih.gov/pubmed/34529289
http://dx.doi.org/10.1111/ctr.14487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285033/
https://www.ncbi.nlm.nih.gov/pubmed/34529289
http://dx.doi.org/10.1111/ctr.14487

Ejemplares similares